Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib

Ruxolitinib was an effective salvage therapy for relapsed/refractory secondary hemophagocytic lymphohistiocytosis. Prolonged maintenance with a ruxolitinib taper obviated the need for intensive chemotherapy or allogeneic transplant in secondary HLH.

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Goldsmith, Scott R., Saif Ur Rehman, Sana, Shirai, Cara L., Vij, Kiran, DiPersio, John F.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2019
Aiheet:
Exceptional Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6963250/
https://ncbi.nlm.nih.gov/pubmed/31821455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000898
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia